SG11201406733QA - Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation - Google Patents
Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregationInfo
- Publication number
- SG11201406733QA SG11201406733QA SG11201406733QA SG11201406733QA SG11201406733QA SG 11201406733Q A SG11201406733Q A SG 11201406733QA SG 11201406733Q A SG11201406733Q A SG 11201406733QA SG 11201406733Q A SG11201406733Q A SG 11201406733QA SG 11201406733Q A SG11201406733Q A SG 11201406733QA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazothiadiazole
- par4
- inhibitors
- platelet aggregation
- activated receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638567P | 2012-04-26 | 2012-04-26 | |
| PCT/US2013/037884 WO2013163241A1 (en) | 2012-04-26 | 2013-04-24 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406733QA true SG11201406733QA (en) | 2014-11-27 |
Family
ID=48225151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406733QA SG11201406733QA (en) | 2012-04-26 | 2013-04-24 | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9518064B2 (en) |
| EP (1) | EP2855489B1 (en) |
| JP (1) | JP6101343B2 (en) |
| KR (1) | KR20150003766A (en) |
| CN (1) | CN104640869B (en) |
| AU (1) | AU2013251680A1 (en) |
| BR (1) | BR112014026651A8 (en) |
| CA (1) | CA2871599A1 (en) |
| EA (1) | EA201491954A1 (en) |
| ES (1) | ES2617879T3 (en) |
| IL (1) | IL235141A0 (en) |
| MX (1) | MX2014012741A (en) |
| SG (1) | SG11201406733QA (en) |
| WO (1) | WO2013163241A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013251683A1 (en) | 2012-04-26 | 2014-12-18 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
| EP3243826B1 (en) | 2012-04-26 | 2019-10-30 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
| MX2016012246A (en) | 2014-03-24 | 2017-01-19 | Bayer Cropscience Ag | Phenylpiperidinecarboxamide derivatives as fungicides. |
| US9598419B1 (en) | 2014-06-24 | 2017-03-21 | Universite De Montreal | Imidazotriazine and imidazodiazine compounds |
| US9617279B1 (en) | 2014-06-24 | 2017-04-11 | Bristol-Myers Squibb Company | Imidazooxadiazole compounds |
| WO2016134450A1 (en) | 2015-02-26 | 2016-09-01 | Université de Montréal | Imidazopyridazine and imidazothiadiazole compounds |
| WO2016138199A1 (en) | 2015-02-26 | 2016-09-01 | Bristol-Myers Squibb Company | Benzothiazole and benzothiophne compounds |
| US9789087B2 (en) | 2015-08-03 | 2017-10-17 | Thomas Jefferson University | PAR4 inhibitor therapy for patients with PAR4 polymorphism |
| ES2900014T3 (en) | 2015-10-19 | 2022-03-15 | Univ Montreal | Heterocyclic compounds as inhibitors of platelet aggregation |
| US20190119300A1 (en) * | 2016-04-18 | 2019-04-25 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
| WO2018013772A1 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Monocyclic heteroaryl substituted compounds |
| WO2018013770A1 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| CN109689664B (en) * | 2016-07-14 | 2022-04-15 | 百时美施贵宝公司 | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors |
| US20190292176A1 (en) | 2016-07-14 | 2019-09-26 | Bistol-Myers Squibb Company | Bicyclic heteroaryl substituted compounds |
| ES2926580T3 (en) * | 2016-12-23 | 2022-10-27 | Minoryx Therapeutics S L | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
| WO2019149205A1 (en) * | 2018-01-31 | 2019-08-08 | 江苏恒瑞医药股份有限公司 | Benzoheteroaryl derivative and preparation method and medical application thereof |
| CN110218218B (en) * | 2018-03-01 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | Benzofuran derivative, preparation method and medical application thereof |
| CN112074522B (en) * | 2018-05-16 | 2022-08-26 | 深圳信立泰药业股份有限公司 | Compounds as protease activated receptor 4(PAR4) inhibitors for the treatment of platelet aggregation |
| WO2019218955A1 (en) * | 2018-05-16 | 2019-11-21 | 深圳信立泰药业股份有限公司 | Compound as protease activated receptor 4 (par4) inhibitor for treating platelet aggregation |
| CN110627817B (en) * | 2018-06-25 | 2022-03-29 | 中国药科大学 | Imidazocyclic PAR4 antagonist and medical application thereof |
| CN111349105B (en) * | 2018-12-24 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | Benzofuran derivative, preparation method and medical application thereof |
| CN109651126A (en) * | 2019-01-17 | 2019-04-19 | 杭州师范大学 | A kind of preparation method of tetraphenyl ethylene yl carboxylic acid organic ligand and its complex |
| CN113150005B (en) * | 2021-04-09 | 2022-08-30 | 中国药科大学 | Quinoxaline compound, preparation method and application thereof in medicine |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2823686A1 (en) | 1978-05-31 | 1979-12-06 | Bayer Ag | IMIDAZO SQUARE BRACKETS ON 2.1 SQUARE BRACKETS FOR SQUARE BRACKETS ON 1.3.4 SQUARE BRACKETS FOR -THIADIAZOLE |
| DE3020421A1 (en) | 1980-05-29 | 1981-12-10 | Bayer Ag, 5090 Leverkusen | IMIDAZOAZOLALIC ACID AMIDES, NEW INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS |
| NO811630L (en) | 1980-05-29 | 1981-11-30 | Bayer Ag | IMIDAZOAZOLYLIC ACID AMOIDS, NEW INTERMEDIATE PRODUCTS FOR THEIR PREPARATION, THEIR PREPARATION AND THEIR USE AS A MEDICINE |
| DE3446778A1 (en) | 1984-12-21 | 1986-07-03 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW IMIDAZO DERIVATIVES, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
| US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| EP0497258B1 (en) | 1991-01-29 | 2002-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer |
| JP2928079B2 (en) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1- (Substituted benzyl) -3- (substituted aryl) condensed pyrazoles, their production and use |
| DE69941777D1 (en) | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THESE AS ACTIVE ACTIVE SUBSTANCES |
| DE19948434A1 (en) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substance library containing bicyclic imidazo-5-amines and / or bicyclic imidazo-3-amines |
| MXPA02002837A (en) | 1999-10-08 | 2002-08-30 | Gr Nenthal Gmbh | Bicyclic imidazo 5 yl amine derivatives. |
| DE10019714A1 (en) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salts of bicyclic, N-acylated imidazo-3-amines and imidazo-5-amines |
| US6387942B2 (en) | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
| US6673815B2 (en) | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CA2364985A1 (en) * | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
| WO2004063159A1 (en) | 2003-01-10 | 2004-07-29 | Idemitsu Kosan Co., Ltd. | Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same |
| EP1636242A1 (en) | 2003-06-13 | 2006-03-22 | Aegera Therapeutics Inc. | Acylated imidazo (2,1-b) -1,3,4,-thiadia zole-2-sulfonamides, and uses thereof |
| CA2527903A1 (en) | 2003-06-13 | 2004-12-23 | Aegera Therapeutics, Inc. | Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxides and sulfones |
| US7767670B2 (en) | 2003-11-13 | 2010-08-03 | Ambit Biosciences Corporation | Substituted 3-carboxamido isoxazoles as kinase modulators |
| CA2555263A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| CA2617319A1 (en) | 2005-06-24 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Radiolabeled-pegylation of ligands for use as imaging agents |
| WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| NL2000397C2 (en) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclic heteroaryl compounds as PDE10 inhibitors. |
| CA2646430A1 (en) | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| US20090170845A1 (en) | 2006-04-13 | 2009-07-02 | Aegera Therapeutics Inc. | USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN |
| DE102006054757A1 (en) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Novel aza-bicyclic compounds and their use |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| US20110206607A1 (en) | 2007-05-10 | 2011-08-25 | Roger Olsson | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| JP2010535773A (en) | 2007-08-10 | 2010-11-25 | グラクソスミスクライン エルエルシー | Nitrogen-containing bicyclic chemicals for treating viral infections |
| WO2009027733A1 (en) | 2007-08-24 | 2009-03-05 | Astrazeneca Ab | (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents |
| GB0718735D0 (en) | 2007-09-25 | 2007-11-07 | Prolysis Ltd | Antibacterial agents |
| CA2710016A1 (en) | 2007-12-21 | 2009-07-02 | The University Of Sydney | Translocator protein ligands |
| AU2009211890B2 (en) * | 2008-02-05 | 2014-03-13 | Sanofi-Aventis | Imidazopyridazines as PAR1 inhibitors, production thereof, and use thereof as medicaments |
| MX2010010562A (en) | 2008-03-31 | 2010-12-07 | Metabolex Inc | Oxymethylene aryl compounds and uses thereof. |
| KR101718386B1 (en) | 2008-09-26 | 2017-03-21 | 내셔날 헬스 리서치 인스티튜트 | Fused multicyclic compounds as protein kinase inhibitors |
| CN102264737A (en) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | Anti-viral compounds |
| FR2948521B1 (en) | 2009-07-21 | 2012-01-27 | Dxo Labs | METHOD OF ESTIMATING A DEFECT OF AN IMAGE CAPTURE SYSTEM AND ASSOCIATED SYSTEMS |
| KR101692126B1 (en) * | 2009-12-18 | 2017-01-02 | 미쓰비시 타나베 파마 코퍼레이션 | Novel antiplatelet agent |
| CN102372701A (en) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | Azabicyclo hexane derivative, preparation method, and application of azabicyclo hexane derivative in medicine |
| KR20130098334A (en) | 2010-08-11 | 2013-09-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Heteroaryls and uses thereof |
| JP2014524472A (en) | 2011-08-22 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | 2-Spiro-substituted iminothiazines and their monooxides and dioxides as BACE inhibitors, compositions, and uses thereof |
| AU2013251683A1 (en) | 2012-04-26 | 2014-12-18 | Bristol-Myers Squibb Company | Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation |
| EP3243826B1 (en) | 2012-04-26 | 2019-10-30 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| KR102178590B1 (en) | 2012-07-18 | 2020-11-13 | 유니버시티 오브 노트르 담 듀락 | 5,5-heteroaromatic anti-infective compounds |
-
2013
- 2013-04-24 WO PCT/US2013/037884 patent/WO2013163241A1/en active Application Filing
- 2013-04-24 SG SG11201406733QA patent/SG11201406733QA/en unknown
- 2013-04-24 CA CA 2871599 patent/CA2871599A1/en not_active Abandoned
- 2013-04-24 JP JP2015509093A patent/JP6101343B2/en active Active
- 2013-04-24 BR BR112014026651A patent/BR112014026651A8/en not_active IP Right Cessation
- 2013-04-24 ES ES13719360.3T patent/ES2617879T3/en active Active
- 2013-04-24 US US14/396,831 patent/US9518064B2/en active Active
- 2013-04-24 KR KR20147030172A patent/KR20150003766A/en not_active Application Discontinuation
- 2013-04-24 CN CN201380033473.5A patent/CN104640869B/en active Active
- 2013-04-24 EP EP13719360.3A patent/EP2855489B1/en active Active
- 2013-04-24 AU AU2013251680A patent/AU2013251680A1/en not_active Abandoned
- 2013-04-24 MX MX2014012741A patent/MX2014012741A/en unknown
- 2013-04-24 EA EA201491954A patent/EA201491954A1/en unknown
-
2014
- 2014-10-19 IL IL235141A patent/IL235141A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014026651A2 (en) | 2017-06-27 |
| EP2855489B1 (en) | 2017-01-04 |
| IL235141A0 (en) | 2014-12-31 |
| US9518064B2 (en) | 2016-12-13 |
| AU2013251680A1 (en) | 2014-11-13 |
| JP6101343B2 (en) | 2017-03-22 |
| CN104640869B (en) | 2017-12-12 |
| KR20150003766A (en) | 2015-01-09 |
| US20150119390A1 (en) | 2015-04-30 |
| EP2855489A1 (en) | 2015-04-08 |
| CN104640869A (en) | 2015-05-20 |
| JP2015514806A (en) | 2015-05-21 |
| WO2013163241A1 (en) | 2013-10-31 |
| ES2617879T3 (en) | 2017-06-20 |
| EA201491954A1 (en) | 2015-01-30 |
| CA2871599A1 (en) | 2013-10-31 |
| MX2014012741A (en) | 2015-04-13 |
| BR112014026651A8 (en) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1203953A1 (en) | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation 4(par4) | |
| IL235141A0 (en) | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation | |
| IL235140A0 (en) | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation | |
| HK1214525A1 (en) | Activin-actrii antagonists and uses for treating bone and other disorders -actrii | |
| EP2920149A4 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| HK1201521A1 (en) | Heterocyclic compounds and methods for their use | |
| PL2812374T3 (en) | Cold-box-binder systems and mixtures for use as additives for such systems | |
| HK1201533A1 (en) | Heterocyclic compounds and methods for their use | |
| HK1201531A1 (en) | Heterocyclic compounds and methods for their use | |
| EP2907593A4 (en) | Method for treating used absorbent article | |
| EP2872143A4 (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation | |
| HK1206350A1 (en) | 2h-imidazol-4-amine compounds and their use as bace inhibitors 2h--4- bace | |
| HK1212331A1 (en) | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors parp-1 4-- | |
| PL2830980T3 (en) | Device for the creation of packaged units | |
| SG11201406345XA (en) | Carboxamide compounds and their use as calpain inhibitors v | |
| GB201217405D0 (en) | Protein removal agent |